Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 1.00 |
| ▸ | FCER2 | P06734 | 13/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 6/20 | 1.00 |
| ▸ | MMP7 | P09237 | 4/20 | 1.00 |
| ▸ | MMP8 | P22894 | 4/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 3/20 | 1.00 |
| ▸ | MMP9 | P14780 | 3/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | MMP14 | P50281 | 3/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batimastat SCHEMBL22803645 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL20793035 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12336015 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL10052355 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12561510 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL4333 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL17521974 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL22847464 | 0.95 | MMP1 (0.91) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL25602210 | 0.91 | MMP1 (0.83) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL23258231 | 0.91 | MMP1 (0.86) | MMP1FCER2MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22032 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| EP-4644418-A1 | NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Hebei Senlang Biotechnology Co. Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025226325-A2 | IN VITRO SYSTEMS FOR GENERATION OF SKIN EQUIVALENTS AND USES THEREOF AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONNECTIVE TISSUE DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250241990-A1 | THERAPEUTIC AGENT | SELECTIMMUNE PHARMA IB (SE) | 2025-07-31 | — | — | US | claimed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0883398-A4 | METHOD OF INHIBITING PHOTOAGING OF SKIN | UNIV MICHIGAN (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0883398-A1 | METHOD OF INHIBITING PHOTOAGING OF SKIN | THE UNIVERSITY OF MICHIGAN (US) | 1998-12-16 | — | — | EP | claimed |
| WO-1998052575-A1 | USE OF METALLOPROTEINASE INHIBITORS IN THE TREATMENT AND PREVENTION OF PULMONARY EMPHYSEMA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-11-26 | — | — | WO | claimed |
| US-5837224-A | Method of inhibiting photoaging of skin | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-11-17 | — | — | US | claimed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998024474-A1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING (DK) | 1998-06-11 | — | — | WO | claimed |
| WO-1997025969-A1 | METHOD OF INHIBITING PHOTOAGING OF SKIN | THE UNIVERSITY OF MICHIGAN (US) | 1997-07-24 | — | — | WO | claimed |